Seres Therapeutics (MCRB) EBITDA (2014 - 2026)
Seres Therapeutics (MCRB) posted EBITDA of -$20.9 million for Q1 2026, down 7.9% sequentially from -$19.4 million in Q4 2025, and up 23.24% YoY from -$17.0 million in Q1 2025.
Seres Therapeutics (MCRB) EBITDA (2014 - 2026) Analysis & Trends
Seres Therapeutics has reported EBITDA for 13 years, with the latest figure at -$20.9 million in Q1 2026.
- Quarterly EBITDA rose 23.24% year-over-year to -$20.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$87.6 million (up 23.2% YoY) and the FY2025 annual result came in at -$94.0 million, up 22.54% from the prior year.
- EBITDA retreated to -$20.9 million in Q1 2026 per MCRB's latest filing, from -$19.4 million in the prior quarter.
- Over five years, EBITDA peaked at $49.5 million in Q2 2023 and troughed at -$70.6 million in Q1 2023.
- A 5-year average of -$30.5 million and a median of -$28.9 million in 2024 frame the typical range for EBITDA.
- The widest YoY moves for EBITDA: up 178.21% in 2023, down 2038.88% in 2023.
- Over 5 years, EBITDA stood at -$1.7 million in 2022, then tumbled by 2038.88% to -$37.0 million in 2023, then rose by 22.12% to -$28.8 million in 2024, then surged by 32.8% to -$19.4 million in 2025, then declined by 7.9% to -$20.9 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$20.9 million, -$19.4 million, and -$22.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Seres Therapeutics | 43.82 Mn | 43.82 Mn | - | -21.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -21.27 Mn |
| Mar 31, 2026 | -20.91 Mn |
| Dec 31, 2025 | -19.38 Mn |
| Sep 30, 2025 | -22.48 Mn |
| Jun 30, 2025 | -24.88 Mn |
| Mar 31, 2025 | -27.24 Mn |
| Dec 31, 2024 | -28.84 Mn |
| Sep 30, 2024 | -29.17 Mn |
| Jun 30, 2024 | -28.87 Mn |
| Mar 31, 2024 | -34.44 Mn |
| Dec 31, 2023 | -37.02 Mn |
| Sep 30, 2023 | -44.59 Mn |
| Jun 30, 2023 | 49.52 Mn |
| Mar 31, 2023 | -70.57 Mn |
| Dec 31, 2022 | -1.73 Mn |
| Sep 30, 2022 | -59.11 Mn |
| Jun 30, 2022 | -63.33 Mn |
| Mar 31, 2022 | -55.75 Mn |
| Dec 31, 2021 | -49.43 Mn |
| Sep 30, 2021 | 68.41 Mn |